Neuroendocrine Cancer NETs Research Appeal

Few have heard of this cancer that currently impacts over 15,000 people in the UK and can affect anyone, of any gender, and at any age. We are fundraising for pioneering research to help us understand how NETs develop, why they present so aggressively in some cases, and why cells show a tendency to change their structure. Our aim is to improve treatment efficacy. Thanks to your extraordinary generosity and some extraordinary extra match funding, we have exceeded our original match funding goal and are continuing to fundraise to reach our new appeal target of £500,000 (of which we have raised over £245,000). Your support today will help to drive this research achieve more, faster, for those living with the most aggressive and debilitating forms of neuroendocrine cancer.

Registered Charity in England and Wales (1165672)

Check mark Match funded

Campaign target


Amount raised


Time left

77 days




  • CancerCancer
  • Medical ResearchMedical Research


  • General Public/HumankindGeneral Public/Humankind


United Kingdom


For many people living with neuroendocrine tumours (NETs), the progression of the cancer is slow but for some people it presents aggressively–it may grow rapidly and spread to other parts of the body, causing a range of debilitating symptoms. Clinicians are yet to understand how people develop NETs, and why they present so aggressively in some and why tumours change their cell structure. Research in this area is chronically underfunded, and further study is urgently needed to improve treatment.


The Royal Free London houses the globally renowned neuroendocrine tumour (NET) research unit led by world-leading specialist Professor Martyn Caplin. Professor Caplin will use genomic profiling to research the impact of the heterogeneity of NETs on treatment efficacy, exploring why some cells within a patient are more aggressive, and why they change their structure and respond to treatment. This will speed up the prediction of treatment efficacy and facilitate the development of new therapies.